Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $27.0752W HIGH $61.76
Volume
1.26 M
Value Traded
42.59 M
Short % Float
19.27%
-2.79%Week
-23.86%1 Month
-22.87%3 Month
-14.8%6 Month
+73.01%5 Year
+237.75%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.14 B
EPS (TTM)
-3.35
P/E Ratio
-
Ent. Value
4.84 B
Total Shares
121.79 M
Float Shares
100.69 M
Insiders
17.32%
Institutions
101.24%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SRRK Catalyst Timeline
Dated clinical, regulatory and corporate events for Scholar Rock Holding Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Scholar Rock Holding Corporation
413Total events
18Upcoming
86Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
●EU MAA SubmissionApitegromabApprovedEx-US Regulatory
Scholar Rock resubmits apitegromab MAA to EMA for SMA
Spinal Muscular Atrophy (SMA)source ↗
▲Product LaunchISEMBYLDApprovedPost-Market
ISEMBYLD launch underway in the U.S.
Spinal Muscular Atrophy (SMA)source ↗
●R&D DayPresentation
Scholar Rock to host investor call on Monday, September 14, 2026, at 8:00 a.m. ET
▲FDA ApprovalISEMBYLDApprovedFDA Decision
FDA approves ISEMBYLD (apitegromab-mstn) for SMA
Spinal Muscular Atrophy (SMA)source ↗
▲PRV GrantedISEMBYLDApprovedDesignation
Scholar Rock awarded Rare Pediatric Disease Priority Review Voucher with ISEMBYLD approval
Spinal Muscular Atrophy (SMA)source ↗
▲FDA ApprovalApitegromabApprovedFDA Decision
FDA approves ISEMBYLD (apitegromab-mstn) for SMA in adults and pediatric patients 2 years and older
Spinal Muscular Atrophy (SMA)source ↗
▲Fast Track DesignationApitegromabApprovedDesignation
FDA granted Fast Track designation to apitegromab for FSHD
FSHDsource ↗
▲Orphan Drug DesignationApitegromabApprovedDesignation
FDA granted Orphan Drug designation to apitegromab for FSHD
FSHDsource ↗
▲First Patient DosedApitegromabApprovedTrial
Participant dosing commenced in Phase 2 FORGE trial
FSHDsource ↗
▲Product LaunchISEMBYLDApprovedPost-Market
ISEMBYLD U.S. commercial launch underway; product available to ship in the coming days
Spinal Muscular Atrophy (SMA)source ↗
●BLA SubmissionApitegromabApprovedRegulatory Filing
Apitegromab BLA submitted for SMA
spinal muscular atrophy (SMA)source ↗
▲Other Regulator MilestoneApitegromabApprovedEx-US Regulatory
PMDA alignment for JNDA filing
spinal muscular atrophysource ↗
▲FDA Feedback ReceivedApitegromabApprovedFDA Meeting
FDA guidance to remove Catalent Indiana from BLA
spinal muscular atrophy (SMA)source ↗
●Manufacturing MilestoneApitegromabApprovedCMC / Inspection
Removed Catalent Indiana as fill-finish facility from BLA
spinal muscular atrophysource ↗
▼EU MAA SubmissionApitegromabApprovedEx-US Regulatory
MAA withdrawn for apitegromab
spinal muscular atrophysource ↗
▼FDA Feedback ReceivedApitegromabApprovedFDA Meeting
FDA classified Catalent Indiana fill-finish facility inspection as Official Action Indicated (OAI)
spinal muscular atrophy (SMA)source ↗
▲Manufacturing MilestoneApitegromabApprovedCMC / Inspection
Data package for second fill-finish facility submitted to FDA
spinal muscular atrophysource ↗
▼Form 483 IssuedApitegromabApprovedCMC / Inspection
FDA classified Catalent Indiana inspection as OAI
spinal muscular atrophysource ↗
▲FDA Filing AcceptedApitegromabApprovedRegulatory Filing
FDA accepted apitegromab BLA for SMA
spinal muscular atrophy (SMA)source ↗
◆Pre Approval InspectionApitegromabApprovedCMC / Inspection
FDA completed reinspection of Catalent Indiana
spinal muscular atrophy (SMA)source ↗
●Enrollment UpdateApitegromabApprovedTrial
Enrollment progressing in Phase 2 OPAL trial
spinal muscular atrophy (SMA)source ↗
●Trial CompletionApitegromabApprovedTrial
Phase 1 study of subcutaneous apitegromab completed
healthy volunteerssource ↗
◆CHMP Positive OpinionApitegromabApprovedEx-US Regulatory
CHMP opinion for apitegromab MAA for SMA
spinal muscular atrophysource ↗
●Manufacturing MilestoneApitegromabApprovedCMC / Inspection
Commercial supply from second fill-finish facility expected early Q3 2026
spinal muscular atrophy (SMA)source ↗
▲Product LaunchApitegromabApprovedPost-Market
US launch of apitegromab in Q3
spinal muscular atrophysource ↗
◆Oral PresentationPresentation
Oral presentation at 2026 International Research Congress on FSHD
Facioscapulohumeral Muscular Dystrophy (FSHD)source ↗
◆EU MAA SubmissionApitegromabApprovedEx-US Regulatory
EMA MAA decision expected mid-2026
spinal muscular atrophysource ↗
●Trial InitiationApitegromabApprovedTrial
Phase 2 FORGE trial initiation expected in mid-2026
facioscapulohumeral muscular dystrophy (FSHD)source ↗
◆Other Regulator MilestoneApitegromabApprovedEx-US Regulatory
EMA decision on apitegromab MAA anticipated
spinal muscular atrophy (SMA)source ↗
◆CHMP Positive OpinionApitegromabApprovedEx-US Regulatory
CHMP opinion for apitegromab MAA anticipated near mid-2026
spinal muscular atrophy (SMA)source ↗
◆Oral PresentationPresentation
Scholar Rock management to present at BofA Securities 2026 Health Care Conference
▲FDA Filing AcceptedApitegromabApprovedRegulatory Filing
FDA accepted apitegromab BLA
spinal muscular atrophysource ↗
◆FDA Feedback ReceivedApitegromabApprovedFDA Meeting
FDA completed reinspection of Catalent Indiana facility
spinal muscular atrophysource ↗
●Enrollment UpdateApitegromabApprovedTrial
Enrollment progressing in Phase 2 OPAL trial
spinal muscular atrophy (infants/toddlers)source ↗
●Trial CompletionApitegromabApprovedTrial
Phase 1 subcutaneous formulation study completed
healthy volunteerssource ↗
●Trial InitiationApitegromabApprovedTrial
Phase 2 FORGE trial on track to initiate in mid-2026
facioscapulohumeral muscular dystrophy (FSHD)source ↗
◆EU ApprovalApitegromabApprovedEx-US Regulatory
EMA decision on apitegromab MAA expected in mid-2026
spinal muscular atrophy (SMA)source ↗
●BLA SubmissionApitegromabApprovedRegulatory Filing
Resubmission of BLA to FDA for apitegromab in SMA
Spinal Muscular Atrophy (SMA)source ↗
●Type C MeetingApitegromabApprovedFDA Meeting
Type C meeting with FDA on second fill-finish facility data package
spinal muscular atrophy (SMA)source ↗
●BLA SubmissionApitegromabApprovedRegulatory Filing
BLA submission for apitegromab
spinal muscular atrophy (SMA)source ↗
◆Oral PresentationPresentation
Management presentation at 44th Annual J.P. Morgan Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How SRRK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-11 | apitegromab | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$174M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.0x
rNPV / MCap
Top 46%
Small Cap(rank 304 of 660)
Percentile Rank
Scholar Rock Holding Corporation faces pipeline headwinds (38/100), with $268M risk-adjusted pipeline value, led by SRK-181 in Cancer (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SRK-181 Monoclonal antibodyCompletedNCT04291079 | Cancer | Phase 1 | COMPLETED | 112 | Apr 14, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every SRRK program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| apitegromab PriorityFast TrackOrphan+1 | obesity | Phase 2 | 2025-06-18 | 100 subjects with obesityRead More | Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss • Patients receiving apitegromaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| FLIER JEFFREY S.Director | Sell | -1,568 29,341 held | $53.53 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SRRK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 31.2 % (-5.2 %) | 379.37 M | 6.90 M |
SRRK Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SRRK ranks across every disease it competes in
Competitive Position is a premium feature
See how SRRK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSRRK News
SRRK▼ -0.5%today
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
Scholar Rock has resubmitted its Marketing Authorisation Application for apitegromab to the European Medicines Agency. This application targets the treatment of spinal muscular atrophy in both children and adults. The decision follows ongoing discussions with regulatory authorities, reflecting the company's commitment to addressing this rare disease.
Read more →SRRKScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock has announced the granting of inducement equity awards to ten new employees, totaling 83,102 shares. This includes stock options for 23,801 shares and restricted stock units for 59,301 shares. These awards are designed to attract talent and are subject to specific terms and conditions.
Read more →SRRK▼ -6.4%on this news
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
Scholar Rock has received FDA approval for ISEMBYLD (apitegromab-mstn), marking it as the first muscle-targeted treatment for spinal muscular atrophy (SMA). This approval applies to both adults and children aged two years and older who are currently on SMN2-targeted therapies. The treatment aims to improve the lives of patients suffering from this debilitating condition.
Read more →SRRKScholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
Scholar Rock has received Fast Track and Orphan Drug designations from the FDA for its drug apitegromab, aimed at treating facioscapulohumeral muscular dystrophy (FSHD). The company has also initiated participant dosing in the Phase 2 FORGE trial. This development highlights the potential of apitegromab in addressing a significant unmet medical need.
Read more →SRRKScholar Rock to Present at Upcoming Investor Conferences
Scholar Rock, a biopharmaceutical company focused on neuromuscular diseases, announced its participation in upcoming investor conferences. The company will engage in a fireside chat at the Cantor 2026 Global Healthcare Conference on September 9. This involvement reflects Scholar Rock's commitment to enhancing visibility and investor relations.
Read more →SRRKScholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
Scholar Rock has provided an update on its regulatory progress for apitegromab, a treatment for spinal muscular atrophy (SMA). The company has successfully removed Catalent Indiana LLC as a commercial fill-finish facility from its Biologics License Application (BLA). This move is expected to enhance the efficiency of the regulatory process.
Read more →SRRKScholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
Scholar Rock announced that the FDA is reviewing its Biologics License Application for apitegromab, aimed at treating spinal muscular atrophy (SMA). The review is progressing alongside the establishment of a second fill-finish facility. The company anticipates an approval decision by September 30, 2026.
Read more →SRRK▲ +10%on this newsshared move
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Scholar Rock has reported its financial results for Q2 2026, highlighting significant progress towards regulatory approval of the world's first myostatin inhibitor. The company focuses on treating rare and severe neuromuscular diseases, leveraging its expertise in myostatin biology. This update reflects both financial stability and promising developments in their pipeline.
Read more →SRRKScholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
Scholar Rock, a biopharmaceutical company focused on spinal muscular atrophy and other neuromuscular diseases, will present at the Canaccord Genuity 46th Annual Growth Conference. The event is scheduled for August 12, 2026, at 1:30 p.m. ET in Boston, MA. This presentation underscores the company's commitment to advancing its research and development efforts.
Read more →SRRKScholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
Scholar Rock has provided an update regarding the anticipated timing of the Committee for Medicinal Products for Human Use (CHMP) opinion on its marketing authorisation application for apitegromab. This application is aimed at treating spinal muscular atrophy in both children and adults. The news suggests that the company is making progress in its efforts to secure approval for this important treatment.
Read more →SRRKScholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
Scholar Rock has announced the date for its second quarter 2026 financial results, which will be reported on August 6, 2026. The company will also host a conference call and webcast for investors at 8:00 a.m. ET on the same day. This initiative reflects Scholar Rock's commitment to keeping stakeholders informed.
Read more →SRRKScholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD
Scholar Rock is set to present its neuromuscular research portfolio at two significant events in 2026: the Annual Cure SMA Research and Clinical Care Meeting and the International Research Congress on FSHD. These platforms will allow the company to share its advancements and findings in neuromuscular diseases. The presentations aim to foster collaboration and innovation in the field.
Read more →SRRK▲ +7%on this news
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Scholar Rock is scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference. The event will provide a platform for the company to discuss its developments and strategic initiatives in the biopharma sector. Further details about the presentation have not been disclosed.
Read more →SRRKScholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
Scholar Rock is set to present at the 2026 Jefferies Global Healthcare Conference. The event will provide a platform for the company to share insights and updates regarding its ongoing projects and future directions. Details about the presentation and topics to be discussed have not been disclosed in the article.
Read more →SRRKScholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
Scholar Rock reported its first quarter 2026 financial results, highlighting the FDA's acceptance of the apitegromab BLA, which is set for a PDUFA date of September 30, 2026. The company is preparing for a commercial launch while continuing to advance its clinical pipeline, including the ongoing Phase 2 OPAL trial. Despite a net loss of $105.5 million, Scholar Rock maintains a strong financial position with $479.9 million in cash.
Read more →SRRKScholar Rock to Present at the BofA Securities 2026 Health Care Conference
Scholar Rock will present at the BofA Securities 2026 Health Care Conference on May 12, 2026. The presentation will focus on the company's efforts to improve treatments for spinal muscular atrophy and other neuromuscular diseases. A live webcast of the event will be available on their website, with a replay accessible for 90 days.
Read more →SRRKScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 17, 2026
Scholar Rock has granted inducement equity awards totaling 89,304 shares to nine new employees. This includes stock options and restricted stock units, aimed at attracting talent under Nasdaq regulations. The awards are part of the company's strategy to enhance its workforce while focusing on developing treatments for spinal muscular atrophy and other rare diseases.
Read more →About Scholar Rock Holding Corporation
Headquarters301 BINNEY STREET, CAMBRIDGE, MA, 02142
BIOPHARMAWATCH ELITE PLUS
Trade the next SRRK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime